Rhumbline Advisers Acquires 7,621 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Rhumbline Advisers increased its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 7.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 115,266 shares of the company’s stock after acquiring an additional 7,621 shares during the quarter. Rhumbline Advisers owned about 0.09% of Organogenesis worth $369,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. SG Americas Securities LLC raised its position in shares of Organogenesis by 66.4% during the 4th quarter. SG Americas Securities LLC now owns 41,746 shares of the company’s stock valued at $134,000 after buying an additional 16,660 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Organogenesis by 54.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after purchasing an additional 1,035,120 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Organogenesis by 107.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 205,943 shares of the company’s stock valued at $589,000 after purchasing an additional 106,823 shares during the last quarter. Barclays PLC lifted its stake in shares of Organogenesis by 251.7% in the 3rd quarter. Barclays PLC now owns 94,809 shares of the company’s stock valued at $271,000 after purchasing an additional 67,855 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Organogenesis by 8.0% in the 3rd quarter. Wellington Management Group LLP now owns 241,648 shares of the company’s stock worth $691,000 after purchasing an additional 17,842 shares during the period. Institutional investors own 49.57% of the company’s stock.

Analyst Ratings Changes

Separately, Morgan Stanley increased their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th.

Organogenesis Stock Performance

ORGO stock opened at $5.16 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The company has a market capitalization of $654.43 million, a P/E ratio of -86.00 and a beta of 1.66. The business has a 50-day moving average price of $3.65 and a 200 day moving average price of $3.35. Organogenesis Holdings Inc. has a 1-year low of $2.17 and a 1-year high of $6.71.

Insider Activity at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now owns 166,879 shares in the company, valued at approximately $851,082.90. The trade was a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Gary S. Gillheeney sold 55,615 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the transaction, the chief executive officer now directly owns 3,044,779 shares in the company, valued at $10,230,457.44. This represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 243,648 shares of company stock valued at $906,969 over the last quarter. 36.90% of the stock is owned by corporate insiders.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.